Esperion Therapeutics Inc., of Ann Arbor, Mich., disclosed full results of a Phase II trial of ETC-1002 in patients with Type II diabetes and hypercholesterolemia

Aspireo Pharmaceuticals Ltd., of Tel Aviv, Israel, reported results of a Phase II study in acromegaly patients showing that Somatoprim, its somatostatin analogue, demonstrated a dose-dependent effect on lowering excess growth hormone in treatment-naïve patients

InnaVirVax, of Evry, France, presented interim results of a Phase I/IIa trial of VAC-3S at the Conference on Retroviruses and Opportunistic Infections in Atlanta, showing safety at three doses tested and immune response among patients in the two highest doses

NeuroDerm Ltd., of Ness Ziona, Israel, said results of a Phase I trial showed Parkinson's candidate ND0612, a formulation of levodopa/carbidopa liquid formula administered continuously subcutaneously through a patch pump, to be safe and tolerable in all tested doses

Teva Pharmaceutical Industries Ltd., of Jerusalem, said results of a Phase III trial of Milprosa (progesterone) vaginal ring were published in Fertility and Sterility

Circassia Ltd., of Oxford, UK, reported results of a Phase II study showing that a short course of four doses of its ToleroMune cat allergy therapy maintained improvements in patient symptoms two years after the start of treatment

Gamida Cell Ltd., of Jerusalem, disclosed results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's NAM technology...The article is based on the results of a Phase I/II study of IFN-alpha-Kinoid in lupus reported in November 2011 during the annual meeting of the American College for Rheumatology

NewLink Genetics Corp., of Ames, Iowa, published results of a Phase I dose-escalation study of HyperAcute Prostate Cancer Immunotherapy in the Journal of Immunotherapy

Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said preliminary results of a Phase II trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's electroporation delivery system showed vaccine-specific antibody responses in all vaccinated subjects evaluated to date

Marina Biotech Inc., of Bothell, Wash., said licensee, ProNAi Therapeutics Inc., of Plymouth, Mich., reported favorable results of a Phase I study with PNT2258, an anti-Bcl-2 cancer drug which uses the company's Smarticles delivery technology

InnaVirVax, of Evry, France, said interim results of a Phase I/IIa trial showed good safety and tolerability for the VAC-3S HIV vaccine

Ariad Pharmaceuticals Inc., of Cambridge, Mass., published results of a Phase I trial of ponatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia in the New England Journal of Medicine

Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., disclosed results of a Phase III study evaluating two levonorgestrel-releasing intrauterine systems, LNG-IUS12 and LNG-IUS16

As a result of the Phase II data, Nabi's board determined that the firm will not issue contingent value rights intended for distribution to shareholders related to NicVAX

One paper described results a Phase I trial in Pelizaeus-Merzbacher disease (PMD), a genetic myelination disorder that afflicts children

Amgen Inc., of Thousand Oaks, Calif., said treatment with RANK ligand inhibitor denosumab decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to results of a Phase II study published in Clinical Cancer Research

The companies said they will present full results of the Phase III studies and additional data from Phase IIb dose-ranging studies of UMEC at upcoming scientific meetings

At the 17th Congress of the European Hematology Association in Amsterdam, Max Topp, of the University of Wuerzberg, Germany presented the results of a Phase II study evaluating the efficacy, safety and tolerability of bispecific antibody blinatumomab (Micromet Inc.) in adult patients with B-precursor acute lymphoblastic leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant

Results of the Phase I dose-escalation study showed the vaccine was safe and well tolerated at all dose levels, with or without adjuvant